New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season
Go back to New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season| CARLISLE COMPANIES, Inc. (NYSE: CSL) | Delayed: 382.03 +6.73 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $375.30 | 52 Week High | $114.49 | |||
| Open | $370.43 | 52 Week Low | $75.17 | |||
| Day High | $382.92 | P/E | 105.83 | |||
| Day Low | $364.00 | EPS | $3.61 | |||
| Volume | 458,510 | |||||
| (AMEX: CSLLY) | Delayed: 90.16 +0.06 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.10 | 52 Week High | $45.60 | |||
| Open | $89.25 | 52 Week Low | $33.39 | |||
| Day High | $90.24 | P/E | N/A | |||
| Day Low | $88.88 | EPS | $0.00 | |||
| Volume | 30,378 | |||||
